Fangyue Guo

809 total citations
30 papers, 543 citations indexed

About

Fangyue Guo is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Fangyue Guo has authored 30 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 12 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Fangyue Guo's work include Pancreatitis Pathology and Treatment (14 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Phagocytosis and Immune Regulation (5 papers). Fangyue Guo is often cited by papers focused on Pancreatitis Pathology and Treatment (14 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Phagocytosis and Immune Regulation (5 papers). Fangyue Guo collaborates with scholars based in China and United States. Fangyue Guo's co-authors include Hong Xiang, Dong Shang, Deshi Dong, Fenglin Hu, Juying Jiao, Xufeng Tao, Qi Zhou, Shilin Xia, Qi Zhou and Dong Shang and has published in prestigious journals such as Cancer Research, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Fangyue Guo

24 papers receiving 535 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fangyue Guo China	15	204	195	138	134	81	30	543
Jeong Yeon Seo South Korea	19	341 1.7×	228 1.2×	103 0.7×	165 1.2×	81 1.0×	35	777
Chien‐Chang Lu Taiwan	15	131 0.6×	158 0.8×	167 1.2×	42 0.3×	71 0.9×	28	547
Meng‐Chiao Hsieh Taiwan	17	171 0.8×	240 1.2×	127 0.9×	34 0.3×	83 1.0×	29	638
Xuehua Piao China	11	86 0.4×	265 1.4×	70 0.5×	123 0.9×	31 0.4×	15	520
Ko‐Chao Lee Taiwan	19	117 0.6×	367 1.9×	190 1.4×	81 0.6×	108 1.3×	54	886
Chun‐Chi Wu Taiwan	18	321 1.6×	265 1.4×	108 0.8×	61 0.5×	43 0.5×	30	875
Honglei Jiang China	12	87 0.4×	254 1.3×	82 0.6×	58 0.4×	28 0.3×	27	522
Xinyu Chang China	14	53 0.3×	259 1.3×	116 0.8×	103 0.8×	37 0.5×	37	578

Countries citing papers authored by Fangyue Guo

Since Specialization

Citations

This map shows the geographic impact of Fangyue Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangyue Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangyue Guo more than expected).

Fields of papers citing papers by Fangyue Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangyue Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangyue Guo. The network helps show where Fangyue Guo may publish in the future.

Co-authorship network of co-authors of Fangyue Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Fangyue Guo. A scholar is included among the top collaborators of Fangyue Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangyue Guo. Fangyue Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Fangyue, Xufeng Tao, Zhi‐Wen Zhai, et al.. (2025). The Peptide–Drug Conjugate M1pep–Tasquinimod Ameliorates Acute Pancreatitis via Selectively Clearing M1-like Macrophages. Biomaterials Research. 29. 250–250.

Wu, Yu, Fangyue Guo, Linlin Lv, et al.. (2025). Targeted inhibitors of S100A9 alleviate chronic pancreatitis by inhibiting M2 macrophage polarization via the TAOK3-JNK signaling pathway. Frontiers in Immunology. 16. 1526813–1526813. 1 indexed citations

Wu, Jing, Yichen Zhang, Fangyue Guo, et al.. (2025). Abstract 3672: High-sensitivity CRISPR-Cas12a detection of prostate-specific antigen based on computationally optimized aptamers. Cancer Research. 85(8_Supplement_1). 3672–3672.

Xiang, Hong, Fangyue Guo, Yu Wu, et al.. (2025). Old drugs with new applications: Tofacitinib-mediated inhibition of M1-like macrophage polarization in acute pancreatitis by the JAK/STAT and emerging NOD-like receptor pathways. International Immunopharmacology. 162. 115135–115135. 1 indexed citations

Guo, Fangyue, Shanfeng Zhang, & Pei Li. (2024). Abstract 4635: RNF208: A novel diagnostic and prognostic biomarker for colorectal cancer and key regulator of malignant behavior. Cancer Research. 84(6_Supplement). 4635–4635.

Guo, Fangyue, et al.. (2024). Abstract 1819: Esculetin modulates SLC31A1 and ATP7B to influence copper homeostasis and trigger cell death in colorectal cancer. Cancer Research. 84(6_Supplement). 1819–1819.

Guo, Fangyue, Jianghao Li, Mengying Liu, et al.. (2024). A magnetic bead-based dual-aptamer sandwich assay for quantitative detection of ciprofloxacin using CRISPR/Cas12a. Molecular and Cellular Probes. 79. 101998–101998. 2 indexed citations

Guo, Fangyue, Xufeng Tao, Yu Wu, et al.. (2024). Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1. Cell Death Discovery. 10(1). 58–58.

Liu, Mengying, Fangyue Guo, Jing Wu, et al.. (2024). Therapeutic potential of esculetin in various cancer types (Review). Oncology Letters. 28(1). 305–305. 5 indexed citations

10.

Yuan, Qihang, et al.. (2023). A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. Functional & Integrative Genomics. 23(3). 263–263. 18 indexed citations

11.

Yu, Hao, Yuying Cui, Fangyue Guo, et al.. (2023). Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy. European Journal of Pharmacology. 962. 176220–176220. 14 indexed citations

12.

Zhou, Qi, Xufeng Tao, Fangyue Guo, et al.. (2023). Tryptophan metabolite norharman secreted by cultivated Lactobacillus attenuates acute pancreatitis as an antagonist of histone deacetylases. BMC Medicine. 21(1). 329–329. 18 indexed citations

13.

Zhou, Qi, Ji Li, Xueying Shi, et al.. (2021). INTS8 is a therapeutic target for intrahepatic cholangiocarcinoma via the integration of bioinformatics analysis and experimental validation. Scientific Reports. 11(1). 23649–23649. 3 indexed citations

14.

Wu, Yu, Qi Zhou, Fangyue Guo, et al.. (2021). S100 Proteins in Pancreatic Cancer: Current Knowledge and Future Perspectives. Frontiers in Oncology. 11. 711180–711180. 20 indexed citations

15.

Hu, Fenglin, et al.. (2020). Macrophages in pancreatitis: Mechanisms and therapeutic potential. Biomedicine & Pharmacotherapy. 131. 110693–110693. 119 indexed citations

16.

Hu, Fenglin, Fangyue Guo, Yutong Zhu, et al.. (2020). IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.. PubMed. 10(11). 3551–3564. 14 indexed citations

17.

Xiang, Hong, et al.. (2020). What we already know about rhubarb: a comprehensive review. Chinese Medicine. 15(1). 88–88. 124 indexed citations

18.

Liu, Han, Qi Zhou, Wen‐Juan Wei, et al.. (2020). The potential drug for treatment in pancreatic adenocarcinoma: a bioinformatical study based on distinct drug databases. Chinese Medicine. 15(1). 26–26. 11 indexed citations

19.

Zhou, Qi, Xufeng Tao, Shilin Xia, et al.. (2020). T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?. Frontiers in Oncology. 10. 382–382. 34 indexed citations

20.

Liu, Chang, Shuang Li, Qingkai Zhang, et al.. (2019). Emerging Role of Chinese Herbal Medicines in the Treatment of Pancreatic Fibrosis. The American Journal of Chinese Medicine. 47(4). 709–726. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact